← All trials
NCT03197922
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 25, 2017
- Primary completion
- Nov 17, 2022
- Completion date
- Nov 17, 2022
- First posted
- Jun 23, 2017
- Last posted
- Dec 15, 2023
- Enrollment
- 117
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Emory UniversityLead sponsor
- Emory UniversityOverall official - principal investigator
- Emory UniversityReponsible party - principal investigator
- Department of DefenseCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.